Synthetic Biology
Ginkgo Bioworks to Go Public With $1.63B in Proceeds From SPAC Merger
The company originally announced its intention to go public through the merger with Soaring Eagle in May and will begin trading on the NYSE on Friday.
Twist Bioscience, Adicet Bio Ink Cancer Collaboration; Barclays Initiates Twist Coverage
Twist will provide its single-chain variable fragment and single-domain VHH antibody (nanobody) technologies to discover unique target-specific binders.
Twist Bioscience Fiscal Q3 Revenues Grow 65 Percent
Twist said that healthcare is now the largest end market for its oligonucleotide products, representing nearly 50 percent of all revenues.
DNA Manufacturer OriCiro Genomics Raises ¥800M in Series B Round
The Japanese company, based in Tokyo, also said that it has secured a long-term loan for about ¥200 million from Japan Finance.
Codex DNA Closes $122.7M IPO
The San Diego-based synthetic nucleic acids company, formerly known as SGI-DNA, sold approximately 7.7 million shares at an offering price of $16 per share.
Jun 11, 2021
May 17, 2021
Ginkgo Bioworks Acquires Dutch DNA Biotech
May 7, 2021
May 6, 2021
Twist Bioscience Q2 Revenues Grow 62 Percent
Mar 18, 2021
Feb 5, 2021
Dec 2, 2020
Twist Bioscience Proposes $250M Public Offering
Nov 23, 2020
Nov 23, 2020
Twist Bioscience Fiscal Q4 Revenues More Than Double
Nov 12, 2020